Ligand Pharmaceuticals Incorporated (LGND) News
Track canonical SquawkNews coverage tagged to LGND, Ligand Pharmaceuticals Incorporated. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 23 indexed stories across 13 publication days and is ordered by the same first-publication timeline used by LiveCast.
L
Ligand Pharmaceuticals Is Maintained at Buy by Citigroup
Ratings actions from Benzinga
NEWS | Sep 23, 2026, 03:23 PM UTC
L
LGND - Sydnexis Announces Royalty Agreement with Ligand for Ryjunea®
LGND - Sydnexis Announces Royalty Agreement with Ligand for Ryjunea®
NEWS | Sep 22, 2026, 01:08 PM UTC
L
LGND - Primrose Bio® Raises Significant Growth Capital Investment Led by Signet Healthcare Partners
LGND - Primrose Bio® Raises Significant Growth Capital Investment Led by Signet Healthcare Partners
NEWS | Sep 22, 2026, 01:05 PM UTC
L
LGND - Ligand Acquires Royalty and Milestone Interest in Santen’s Ryjunea® from Sydnexis for $23 Million
LGND - Ligand Acquires Royalty and Milestone Interest in Santen’s Ryjunea® from Sydnexis for $23 Million
NEWS | Sep 22, 2026, 11:01 AM UTC
L
LGND: XOMA acquisition doubled the portfolio and set the stage for accelerated, diversified growth
LGND: XOMA acquisition doubled the portfolio and set the stage for accelerated, diversified growth
MNA | Aug 26, 2026, 04:11 PM UTC
L
LGND: XOMA acquisition and robust pipeline set the stage for accelerated, diversified growth
LGND: XOMA acquisition and robust pipeline set the stage for accelerated, diversified growth
MNA | Aug 26, 2026, 03:31 PM UTC
L
LGND - Ligand to Participate in September Investor Conferences
LGND - Ligand to Participate in September Investor Conferences
EQUITY | Aug 26, 2026, 11:00 AM UTC
L
Ligand Pharmaceuticals Raises FY2026 Adj EPS Guidance from $8.50-$9.50 to $9.00-$9.50 vs $9.16 Est; Affirms FY2026 Sales Guidance of $270.00
Ligand Pharmaceuticals (NASDAQ: LGND ) raises FY2026 Adj EPS guidance from $8.50-$9.50 to $9.00-$9.50 vs $9.16 analyst estimate. Affirms FY2026 sales outlook from $270.000 million-$310.000 million to $270.000 million-$31
EARNINGS | Aug 06, 2026, 11:05 AM UTC
L
LGND - Ligand Reports Second Quarter 2026 Financial Results
LGND - Ligand Reports Second Quarter 2026 Financial Results
EARNINGS | Aug 06, 2026, 11:00 AM UTC
H
LGND PT Raised to $326
LGND price target increased to $326
EQUITY | Aug 03, 2026, 12:24 PM UTC
L
LGND Initiated Buy W/$387.00 PT at Citi
LGND Initiated Buy W/$387.00 PT at Citi
EQUITY | Jul 21, 2026, 12:09 PM UTC
L
LGND Resume coverage with a Buy/H rating, $387 PT @ Citi
LGND Resume coverage with a Buy/H rating, $387 PT @ Citi
EQUITY | Jul 21, 2026, 10:41 AM UTC
L
LGND Maintain Outperform, raise PT to $340 (from $262) as zero-coupon convert strengthens balance sheet @ RBC
LGND Maintain Outperform, raise PT to $340 (from $262) as zero-coupon convert strengthens balance sheet @ RBC
EQUITY | Jul 15, 2026, 12:32 PM UTC
H
Ligand Pharmaceuticals Closes $739 Million XOMA Royalty Purchase
() -- Ligand Pharmaceuticals (LGND) has completed its acquisition of XOMA Royalty (XOMA) for an equity value of about $739 million, the company said Tuesday. XOMA Royalty shareholders received $39 in cash per share and o
EARNINGS | Jul 14, 2026, 02:00 PM UTC
L
LGND Ligand completes acquisition of Xoma Royalty, creating a portfolio of more than 200 biopharmaceutical Royalty assets
LGND Ligand completes acquisition of Xoma Royalty, creating a portfolio of more than 200 biopharmaceutical Royalty assets
MNA | Jul 14, 2026, 01:00 PM UTC
H
Ligand price target raised to $388 from $266 at BofA
BofA analyst Jason Zemansky raised the firm's price target on Ligand to $388 from $266 and keeps a Buy rating on the shares. Despite strong share performance, Ligand's growth opportunity remains underappreciated, with th
EARNINGS | Jul 09, 2026, 10:19 AM UTC
L
Ligand Pharmaceuticals Insider Sold Shares Worth $1,566,377, According to a Recent SEC Filing
() -- Andrew Reardon, Chief Legal Officer & Secretary, on June 30, 2026, sold 5,000 shares in Ligand Pharmaceuticals (LGND) for $1,566,377. Following the Form 4 filing with the SEC, Reardon has control over a total of 41
REGULATION | Jul 06, 2026, 09:21 PM UTC
L
LGND Closes Notes Offering
Ligand announces closing of convertible senior notes offering
EQUITY | Jun 25, 2026, 08:01 PM UTC
L
CDNL: Proposes Public Offering
CDNL proposes public offering of common stock
EQUITY | Jun 23, 2026, 09:24 AM UTC
M
LGND Prices $625M Notes
Ligand announces pricing of upsized $625 million convertible senior notes offering
EQUITY | Jun 23, 2026, 09:22 AM UTC
M
LGND Prices $625M Notes
Ligand Pharmaceuticals prices upsized $625M 0.0% convertible senior notes offering due 2031 and plans to repurchase shares
EARNINGS | Jun 23, 2026, 08:21 AM UTC
M
LGND Offers $550M Notes
Ligand plans to offer $550M in convertible notes for share buybacks and corporate needs
EQUITY | Jun 22, 2026, 11:15 AM UTC
M
LGND Offers $550M Notes
Ligand announces proposed offering of $550 million of convertible senior notes due 2031
EQUITY | Jun 22, 2026, 11:02 AM UTC